Research funder · United States

Michael J. Fox Foundation for Parkinson's Research

Non-profit organization in the USA

michaeljfox.org

Grants since 2016: 1 275
Awarded, last 5 years (where amounts are published): —
Funded works, last 5 years: 3 085
Funded works, all time: 6 716

Grants

2022 · research · Target Advancement Program

Assessing the Neuroprotective Factor REST/NRSF as a Therapeutic Target for Parkinson’s Disease

Nora Bengoa-Vergniory · Achucarro Basque Center for Neuroscience

2022 · research · Diversity, Equity and Inclusivity in Parkinson's research

Assessing the Awareness, Perception, Diagnosis, and Treatment of Parkinson’s Disease in Africa

2022 · research · Fall 2021 RFP: Expanding Biological Understanding of PD

Examining Fatty Acid Imbalances in Parkinson’s Disease

Saranna Fanning · Brigham and Women's Hospital

2022 · research · MJFF Funded Study

The Heads-Up Trial: Exploring the Effects of Sleeping in a Head-up Tilt Position on Blood Pressure in Parkinson’s Disease

Roland D. Thijs

2022 · research · Expanding Biological Understanding of Parkinson's Disease

Characterization of the Contributions of Alpha-synuclein and Tau Aggregation in a Preclinical Model of Parkinson’s Disease Progression

Michael Henderson · Van Andel Institute

2022 · research · 2022: Accelerated Therapeutics Program

Using Small Molecules that Modulate Mitochondrial Function for the Treatment of Parkinson's Disease

Amy Ripka · Lucy Therapeutics

2022 · research · Parkinson’s Pathway Molecular Data Analysis Program

Developing Biomarker Signatures of Parkinson’s Disease Using a Novel Progression Model

Lana Chahine · University of Pittsburgh

2022 · research · Diversity, Equity and Inclusivity in Parkinson's research

Understanding the Progression of Motor and Non-motor Symptoms and Functional Mobility of Māori and Pacific Peoples in New Zealand

Leigh Hale · University of Otago

2022 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies

Development of Immune-based Biomarkers for Parkinson’s Disease

Katherine Olson · University of Nebraska Medical Center

2022 · research · Therapeutic Pipeline Program

Assessing the Effects of USP30 Inhibitors on the Removal of Damaged Mitochondria in Nerve Cells

Bahareh (Spring) Behrouz · Vincere Biosciences Inc

2022 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies

Assessment of Alpha-synuclein Aggregation Inhibitor ASN121151 as a Potential New Treatment for Parkinson’s Disease

Dirk Beher · Asceneuron S.a.

2022 · research · Target Advancement Program

Targeting GPR43 in T-cells as a Potential Treatment for Parkinson’s Disease

Rodrigo Pacheco · Fundación Ciencia and Vida

2022 · research · Research Grant

Using the Emergence of New Symptoms as a Measure for Parkinson’s Disease Progression in Clinical Trials

Jesse M. Cedarbaum · Coeruleus Clinical Sciences Llc

2022 · research · Diversity, Equity and Inclusivity in Parkinson's research

Risk Factors for Parkinson’s Disease Among Participants in the Black Women’s Health Study

Alberto Ascherio · Harvard University

2022 · research · Target Advancement Program

Alpha-synuclein Aggregation in the Brainstem: Developing a Model and Discovering a New Biomarker for Parkinson Disease

Asad Jan · Aarhus University

2022 · research · Novel PET Tracer Development Program

Screening for PET Tracers that will Bind to the P2Y12 Receptor and Allow Monitoring of Microglia Activation During Neuroinflammation

Luca Gobbi · F. Hoffmann-la Roche Ltd.

2022 · research · Diversity, Equity and Inclusivity in Parkinson's research

Studying Parkinson’s Disease Clinical Features, Progression and Quality of Care in Latino Patients from a Population-based Epidemiological Study in the United States

Beate Ritz · University of California, Los Angeles

2022 · research · Research Grant

Perspective and Consensus on Prevention Planning for Parkinson’s Disease

Michael A. Schwarzschild · Massachusetts General Hospital

2022 · research · Research Grant

Identifying Novel Target Genes and Compounds for Controlling the Motor Symptoms of Parkinson’s Disease

Anatol Kreitzer · Maplight Therapeutics

2022 · research · Fall 2021 RFP: Outcome Measures

Using RNA from Extracellular Vesicles to Monitor RNA Changes in the Brain

Kendall Van Keuren-Jensen · Translational Genomics Research Institute

2022 · research · Proof-of-Concept Testing of PD Therapeutics

Therapeutic Targeting of Mitochondrial Biogenesis to Address Parkinson’s Disease

Lalitha Madhavan · University of Arizona

2022 · research · Magnetic Resonance Imaging Biomarkers

Dynamic Modeling and Prediction of Parkinsonian Symptom Progression

Boris A. Gutman · Imaging Genetics Center, Institute For Neuroimaging And Informatics, University Of Southern Californ

2022 · research · Cellular Phenotyping in Human iPSCS from the PPMI Cohort

Simultaneous Profiling of Gene Expression Patterns from Pooled Cell Samples of Large Parkinson’s Disease Cohorts

Rhalena A. Thomas · McGill University

2022 · research · Research Grant

Using Integrated Biomarkers of Prodromal Parkinson’s Disease to Assess the Efficacy of Exercise Intervention in the Earliest Phase of Disease

Sirwan K.L. Darweesh · Radboud University Medical Center

2022 · research · Parkinson’s Pathway Molecular Data Analysis Program

Investigating the Role of Repeat Expansions and Mitochondrial Dysfunction in Parkinson’s Disease

Melanie Bahlo · Walter and Eliza Hall Institute of Medical Research

2022 · research · Therapeutic Pipeline Program

Developing an Assay to Identify Glucocerebrosidase-enhancing Chaperones for the Treatment of Parkinson’s Disease

Ellen Sidransky · National Human Genome Research Institute

2022 · research · MJFF Funded Study

Fostering Inclusivity in Research Engagement for Underrepresented Populations in Parkinson’s Disease, Phase II (FIRE-UP PD II)

Angie Viviana Sanchez · Massachusetts General Hospital

2022 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies

Using AZP2006 (Ezeprogind) to Stabilize Progranulin – A Novel Therapeutic Strategy for GBA1-linked Parkinson’s Disease

Philippe Verwaezrde · Alzprotect (France)

2022 · research · Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies

Use of Itaconate to Improve Metabolic Regulation in Parkinson's Disease

Pedro Cabrales · University of California San Diego

2022 · research · Spring 2022 RFP: Proof-of-Concept Testing of PD Therapeutics

Project Title: Clinical Development of PDM608, a Potential Neuroprotective and Anti-inflammatory Long-acting Biologic for Parkinson’s Disease

Sean B. Joseph · Calibr, A Division Of Scripps Research

2022 · research · Spring 2022 RFP: Expanding Biological Understanding of Parkinson's Disease

Overcoming Inequity in the Treatment of Parkinson’s Disease: Recognizing and Caring for Underserved Communities in Brazil

Artur Francisco Schumacher Schuh · Universidade Federal do Rio Grande do Sul

2022 · research · Diversity, Equity and Inclusivity in Parkinson's research

Identification and Quantification of Parkinson’s Disease Progression Using Digital Measures from a Wrist-worn Wearable Device - a Retrospective Study

Arvind Ramanujam · Koneksa Health Inc.